Neurogene Inc. Operating Lease Cost
Neurogene Inc. (NGNE) reported Operating Lease Cost of $405.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-08-11
- Neurogene Inc. operating lease, cost for the quarter ending 2026-06-30 was $405.00K, a 14.19% decline year-over-year.
- Neurogene Inc. operating lease, cost for the quarter ending 2026-03-31 was $419.00K, a 13.43% decline year-over-year.
- Neurogene Inc. operating lease, cost for the quarter ending 2025-12-31 was $437.00K, a 11.90% decline year-over-year.
- Neurogene Inc. operating lease, cost for the quarter ending 2025-09-30 was $459.00K, a 9.65% decline year-over-year.
- Neurogene Inc. operating lease, cost for fiscal 2025 was $1.85M, a 9.61% decline from fiscal 2024.
- Neurogene Inc. operating lease, cost for fiscal 2024 was $2.05M, a 97.59% increase from fiscal 2023.
- Neurogene Inc. operating lease, cost for fiscal 2023 was $1.04M, a 0.00% change from fiscal 2022.
- Neurogene Inc. operating lease, cost for fiscal 2022 was $1.04M, a 59.09% decline from fiscal 2021.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month | Operating Lease, Cost 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $405.00K 10-Q · filed 2026-08-11 | $823.00K 10-Q · filed 2026-08-11 | $1.26M derived: sum of 3 quarters · filed 2026-08-11 | $1.72M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2026-03-31 | $419.00K 10-Q · filed 2026-05-12 | $856.00K derived: sum of 2 quarters · filed 2026-05-12 | $1.31M derived: sum of 3 quarters · filed 2026-05-12 | $1.79M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-12-31 | $437.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $896.00K derived: sum of 2 quarters · filed 2026-03-24 | $1.37M derived: sum of 3 quarters · filed 2026-08-11 | $1.85M 10-K · filed 2026-03-24 | |
| 2025-09-30 | $459.00K 10-Q · filed 2025-11-13 | $931.00K derived: sum of 2 quarters · filed 2026-08-11 | $1.42M 10-Q · filed 2025-11-13 | $1.91M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-06-30 | $472.00K 10-Q · filed 2026-08-11 | $956.00K 10-Q · filed 2026-08-11 | $1.45M derived: sum of 3 quarters · filed 2026-08-11 | $1.96M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-03-31 | $484.00K 10-Q · filed 2026-05-12 | $980.00K derived: sum of 2 quarters · filed 2026-05-12 | $1.49M derived: sum of 3 quarters · filed 2026-05-12 | $2.01M derived: sum of 4 quarters · filed 2026-05-12 | |
| 2024-12-31 | $496.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $1.00M derived: sum of 2 quarters · filed 2026-03-24 | $1.52M derived: sum of 3 quarters · filed 2026-03-24 | $2.05M 10-K · filed 2026-03-24 | |
| 2024-09-30 | $508.00K 10-Q · filed 2025-11-13 | $1.03M derived: sum of 2 quarters · filed 2025-11-13 | $1.55M 10-Q · filed 2025-11-13 | $1.81M derived: sum of 4 quarters · filed 2025-11-13 | |
| 2024-06-30 | $519.00K 10-Q · filed 2025-08-11 | $1.04M 10-Q · filed 2025-08-11 | $1.30M derived: sum of 3 quarters · filed 2025-08-11 | $1.56M derived: sum of 4 quarters · filed 2025-08-11 | |
| 2024-03-31 | $524.00K 10-Q · filed 2025-05-09 | $784.00K derived: sum of 2 quarters · filed 2025-05-09 | $1.04M derived: sum of 3 quarters · filed 2025-05-09 | $1.30M derived: sum of 4 quarters · filed 2025-05-09 | |
| 2023-12-31 | $260.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | $519.00K derived: sum of 2 quarters · filed 2025-03-24 | $778.00K derived: sum of 3 quarters · filed 2025-03-24 | $1.04M 10-K · filed 2025-03-24 | |
| 2023-09-30 | $259.00K 10-Q · filed 2024-11-18 | $518.00K derived: sum of 2 quarters · filed 2024-11-18 | $777.00K 10-Q · filed 2024-11-18 | ||
| 2023-06-30 | $259.00K 10-Q · filed 2024-08-09 | $518.00K 10-Q · filed 2024-08-09 | |||
| 2023-03-31 | $259.00K 10-Q · filed 2024-05-10 | ||||
| 2022-12-31 | $1.04M 10-K · filed 2024-03-18 | $2.54M 10-K · filed 2023-03-20 | |||
| 2021-12-31 | $2.54M 10-K · filed 2023-03-20 | ||||
| 2020-12-31 | $2.37M 10-K · filed 2022-03-01 | ||||
| 2020-03-31 | $528.00K 10-Q · filed 2020-05-06 | $639.00K derived: sum of 2 quarters · filed 2021-03-25 | $663.00K derived: sum of 3 quarters · filed 2021-03-25 | $694.00K derived: sum of 4 quarters · filed 2021-03-25 | |
| 2019-12-31 | $111.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $135.00K derived: sum of 2 quarters · filed 2021-03-25 | $166.00K derived: sum of 3 quarters · filed 2021-03-25 | $197.00K 10-K · filed 2021-03-25 | |
| 2019-09-30 | $24.00K 10-Q · filed 2019-11-13 | $55.00K derived: sum of 2 quarters · filed 2019-11-13 | $86.00K 10-Q · filed 2019-11-13 | ||
| 2019-06-30 | $31.00K 10-Q · filed 2019-08-01 | $62.00K 10-Q · filed 2019-08-01 | |||
| 2019-03-31 | $31.00K 10-Q · filed 2020-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |